MAJOR LATE TOXICITIES AFTER CONFORMAL RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA-PATIENT- AND TREATMENT-RELATED RISK FACTORS

被引:100
作者
Lee, Anne W. M. [1 ]
Ng, W. T. [1 ]
Hung, W. M. [1 ]
Choi, C. W. [1 ]
Tung, Raymond [3 ]
Ling, Y. H. [1 ]
Cheng, Peter T. C. [1 ]
Yau, T. K. [1 ]
Chang, Amy T. Y. [1 ]
Leung, Samuel K. C. [2 ]
Lee, Michael C. H. [2 ]
Bentzen, Soren M. [4 ]
机构
[1] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Chaiwan, Hong Kong, Peoples R China
[2] Pamela Youde Nethersole Eastern Hosp, Dept Med Phys, Chaiwan, Hong Kong, Peoples R China
[3] Hong Kong Canc Fund, Hong Kong, Hong Kong, Peoples R China
[4] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 73卷 / 04期
关键词
Nasopharyngeal carcinoma; Late toxicity; Concurrent chemotherapy; Radiation boost; SENSORINEURAL HEARING-LOSS; ACCELERATED FRACTIONATION; CONCURRENT CHEMORADIOTHERAPY; THERAPEUTIC GAIN; NORMAL TISSUE; TUMOR-CONTROL; LOCAL-CONTROL; CHEMOTHERAPY; CANCER; RADIATION;
D O I
10.1016/j.ijrobp.2008.05.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To retrospectively analyze the factors affecting late toxicity for nasopharyngeal carcinoma. Methods and Materials: Between 1998 and 2003, 422 patients were treated with a conformal technique with 2-Gy daily-fractions to a total dose of 70 Gy. Conventional fractionation (5 fractions weekly) was used in 232 patients and accelerated fractionation (6 fractions weekly) in 190 patients. One hundred seventy-one patients were treated with the basic radiotherapy course alone (Group 1), 55 patients had an additional boost of 5 Gy in 2 fractions (Group 2), and 196 patients underwent concurrent cisplatin-based chemotherapy (Group 3). Results: The 5-year overall toxicity rate was significantly greater in Group 3 than in Group 1 (37% vs. 27%, p 0.009). Although the overall rate in Group 2 was not elevated (28% vs. 27%, p = 0.697), a significant increase in temporal lobe necrosis was observed (4.8% vs. 0%,p = 0.015). Multivariate analyses showed that age and concurrent chemotherapy were significant factors. The hazard ratio of overall toxicity attributed to chemotherapy was 1.99 (95% confidence interval, 1.32-2.99,p = 0.001). The mean radiation dose to the cochlea was another significant factor affecting deafness, with a hazard ratio of 1.03 (95 % confidence interval, 1.01-1.05, p = 0.005) per 1-Gy increase. The cochlea that received >50 Gy had a significantly greater deaf rate (Group 1, 18% vs. 7%; and Group 3, 22% vs. 14%). Conclusion: The therapeutic margin for nasopharyngeal carcinoma is extremely narrow, and a significant increase in brain necrosis could result from dose escalation. The significant factors affecting the risk of dearness included age, concurrent chemoradiotherapy, and greater radiation dose to the cochlea. (C) 2009 Elsevier Inc.
引用
收藏
页码:1121 / 1128
页数:8
相关论文
共 28 条
  • [21] Middle cerebral artery stenosis in patients with nasopharyngeal carcinoma after radiotherapy: the incidence of stenosis and the risk factors
    Zhou, Lijuan
    Xing, Pengfei
    Zou, Li
    Shen, Junkang
    Tian, Ye
    Lu, Xueguan
    BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1061)
  • [22] Impact of clinical and therapeutic factors on major late complications after radiotherapy with or without concomitant chemotherapy for anal carcinoma
    Allal, AS
    Mermillod, B
    Roth, AD
    Marti, MC
    Kurtz, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (05): : 1099 - 1105
  • [23] Incidence of late-onset pneumonia in patients after treatment with radiotherapy for nasopharyngeal carcinoma: A nationwide population-based study
    Yen, Ting-Ting
    Lin, Ching-Heng
    Jiang, Rong-San
    Shih, Yi-Ting
    Yen, Hung-Rong
    Liang, Kai-Li
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (12): : 1756 - 1761
  • [24] Treatment-related pneumonitis after thoracic radiotherapy/chemoradiotherapy combined with anti-PD-1 monoclonal antibodies in advanced esophageal squamous cell carcinoma
    Lv, Xiaoyan
    Wu, Yajing
    Li, Qihui
    Zheng, Chen
    Lin, Qiang
    Pang, Qingsong
    Zhao, Min
    Zhang, Jiandong
    Wang, Jun
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (10) : 857 - 866
  • [25] Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study
    Sujenthiran, Arunan
    Nossiter, Julie
    Parry, Matthew
    Charman, Susan C.
    Cathcart, Paul J.
    van der Meulen, Jan
    Clarke, Noel W.
    Payne, Heather
    Aggarwal, Ajay
    RADIOTHERAPY AND ONCOLOGY, 2018, 128 (02) : 357 - 363
  • [26] Intensity-modulated radiotherapy as the boost or salvage treatment of nasopharyngeal carcinoma: The appropriate parameters in the inverse planning and the effect of patient's anatomic factors on the planning results
    Hsiung, CY
    Hunt, MA
    Yorke, ED
    Chui, CS
    Hu, J
    Xiong, JP
    Ling, CC
    Lo, SK
    Wang, CJ
    Huang, EY
    Amols, HI
    RADIOTHERAPY AND ONCOLOGY, 2005, 77 (01) : 53 - 57
  • [27] Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study
    Wang, Gaoyuan
    Huang, Chenglong
    Yang, Kaibin
    Guo, Rui
    Qiu, Youyu
    Li, Wenfei
    Mao, Yanping
    Tang, Linglong
    Ma, Jun
    RADIOTHERAPY AND ONCOLOGY, 2022, 177 : 205 - 213
  • [28] Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)
    Wang, Shulian
    Liao, Zhongxing
    Wei, Xiong
    Liu, Helen H.
    Tucker, Susan L.
    Hu, Chao-Su
    Mohan, Rodhe
    Cox, James D.
    Komaki, Ritsuko
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (05): : 1399 - 1407